Wordt geladen...
Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion
Rapid initiation of eculizumab mitigates progression of carfilzomib-induced aHUS. Development of carfilzomib-induced aHUS may be associated with heterozygous CFHR3-CFHR1 deletion.
Bewaard in:
| Gepubliceerd in: | Blood Adv |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
American Society of Hematology
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6290108/ https://ncbi.nlm.nih.gov/pubmed/30518536 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018027532 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|